A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, blood metabolites, and ...

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...

The dose-escalation study enrolled patients with RRMM who were treated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies and are refractory to, or intolerant of, ...

The proportion of CD38+HLA-DR+CD8+ T cells was significantly higher in the blood of patients with cirrhosis compared to healthy controls. They also showed that the ratio of these cells was strongly ...

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development.

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting ...

CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nature Cancer, 2025; DOI: 10.1038/s43018-025-00934-1 ...

J&J is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the Danish company to discontinue the program.

Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant.